Title : Emerging Treatments of Cardiorenal Syndrome: An Update on Pathophysiology and Management.

Pub. Date : 2021 Aug

PMID : 34540466






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The use of therapeutic agents such as sodium-glucose co-transporter 2 inhibitors and tolvaptan (a vasopressin V2 receptor antagonist), and cardiac resynchronization therapy has also been shown to have potential benefits in managing the disease. Tolvaptan arginine vasopressin receptor 2 Homo sapiens